Travel Health Evidence

Praktično

Jedenje u inostranstvu s celijakijom ili alergijom na hranu

Jezička barijera pretvara upravljano stanje u kockanje. Rješenje je uglavnom logističko i vrijedi ga primijeniti prije nego što krenete.

Ažurirano 2 min čitanja 40 citati Snaga dokaza 3/5

Čekalište u holu za odlazak na aerodromu s redovima sjedala i dnevnom svjetlošću odozgo
Jwh · CC BY-SA 3.0 lu · Wikimedia Commons

Šta EU pravila pružaju

Četrnaest glavnih alergena — uključujući žitarice koje sadrže gluten — mora biti deklarisano širom EU, u pakovanoj hrani i u uslužnoj hrani. Pravila su dovoljno uniformna da putnik s celijakijom koji se kreće između država članica ima isti okvir označavanja, što je značajna i nedovoljno cijenjena prednost.

Ono što varira je sprovođenje, kako uslužna hrana otkriva (usmeno, na meniju, u fasciklu), i kulturna upoznatost sa stanjem. Neke zemlje imaju visoku javnu svijest o celijakiji; druge to tretiraju kao preferencu.

Praktični sistem

  1. Nabavite karticu za prevođenje na lokalnom jeziku, koja medicinski navodi stanje, imenuje šta se mora izbjegavati i spominje zajedničke friteze i površine. Kartica ide u kuhinju; izgovorena rečenica ne ide.
  2. Naučite čitati listu sastojaka, a ne jezik. Alergeni su tipografski naglašeni širom EU, tako da ih možete pronaći bez čitanja ostatka.
  3. Rezervišite smještaj s frižiderom i kuvalom. To pretvara teško putovanje u običan.
  4. Ponesite sigurnu hranu za putne dane. Aerodromi, stanice i duga putovanja su mjesta gdje ljudi bivaju uhvaćeni.
  5. Pronađite lokalnu celijak ili alergijsku asocijaciju. Većina evropskih zemalja ima jednu, nekoliko objavljuje liste mjesta.
  6. Ponesite dovoljno lijekova — uključujući auto-injektore adrenalina gdje je to relevantno — i nosite pismo o receptu.

Osiguranje i dokumentacija

Provjerite da li putno osiguranje pokriva vaše stanje i nosite dokumentaciju o bilo kojim lijekovima u originalnom pakovanju s pismom o receptu. Unutar EU, Evropska zdravstvena kartica pokriva neophodnu državnu medicinsku njegu, što nije isto kao putno osiguranje i ne zamjenjuje ga.

Česta pitanja

Da li su prevodilačke kartice zaista korisne?
Da, više nego govor. Kartica se može predati kuhinji, gdje se donose odluke.
U kojim je evropskim zemljama najlakše s celijakijom?
Svijest varira više nego regulativa. Nacionalna društva za celijakiju trenutno su najbolji izvor, umjesto bilo kakvog uopštavanja.
Da li mogu nositi svoje lijekove preko granice?
Uglavnom da, u originalnom pakovanju s potvrdom o receptu. Posebno provjerite kontrolisane supstance.
Šta ako u inostranstvu unesem gluten?
Upravljajte simptomima i hidratacijom. Ne postoji liječenje za izloženost — pogledajte našu stranicu o celijakiji.
Unutrašnjost uskog tijela aviona sa odjeljcima za prtljag iznad glava i sjedištima u tri reda.
Aykleinman (talk) · Public domain · Wikimedia Commons

Povezano čitanje

Dokazi iza ove stranice Stogasti grafikon koji prikazuje sastav 26 publikacija citiranih na ovoj stranici prema tipu studije. 11855meta-analysis (11)randomised trial (8)review (5)other (5)
29 publikacija, 1987–2026. To je mješavina koja uključuje i ispitivanja i sinteze, što je pozicija iz koje je tvrdnja o uzroku razumna. Izvor: vlastita lista citata ove stranice, ispod.

Reference

Svaka citacija u nastavku povezuje na izvorni recenzirani zapis na PubMed-u ili putem DOI-a. Ništa ovdje nije zamjena za medicinski savjet.

  1. Selected laboratory-based biomarkers for assessing vitamin A deficiency in at-risk individuals Gannon BM, Huey SL, Mehta NH, et al. · The Cochrane database of systematic reviews · 2025 · Meta-analysis DOIPubMed 40433851Full text
  2. Towards shortening the duration of antibiotic therapy for Lyme borreliosis: a systematic review and meta-analysis Raffetin A, Henningsson AJ, Ornstein K, et al. · Infection · 2025 · Meta-analysis DOIPubMed 40246800
  3. Non-pharmacological interventions designed to support carriers of multi-drug-resistant organisms (MDROs): a systematic literature review Gaube S, Pan M, Rath A, et al. · The Journal of hospital infection · 2025 · Systematic review DOIPubMed 40816599
  4. Risk of anaphylaxis on commercial flights Turner PJ · Current opinion in allergy and clinical immunology · 2025 · Systematic review DOIPubMed 40643054Full text
  5. How Common Are Allergic Reactions During Commercial Flights? A Systematic Review and Meta-Analysis Turner PJ, Mamula J, Laktabi J, et al. · The journal of allergy and clinical immunology. In practice · 2023 · Meta-analysis DOIPubMed 37507067
  6. Skin care interventions in infants for preventing eczema and food allergy Kelleher MM, Cro S, Cornelius V, et al. · The Cochrane database of systematic reviews · 2021 · Meta-analysis DOIPubMed 33545739Full text
  7. Whole-cell pertussis vaccine in early infancy for the prevention of allergy in children Perez Chacon G, Ramsay J, Brennan-Jones CG, et al. · The Cochrane database of systematic reviews · 2021 · Systematic review DOIPubMed 34693993Full text
  8. The effectiveness of anti-inflammatory and anti-seizure medication for individuals with single enhancing lesion neurocysticercosis: A meta-analysis and expert group-based consensus recommendations Abraham A, Bustos JA, Carabin H, et al. · PLoS neglected tropical diseases · 2021 · Meta-analysis DOIPubMed 33788843Full text
  9. Considerations on biologicals for patients with allergic disease in times of the COVID-19 pandemic: An EAACI statement Vultaggio A, Agache I, Akdis CA, et al. · Allergy · 2020 · Clinical guideline DOIPubMed 32500526Full text
  10. Exit and Entry Screening Practices for Infectious Diseases among Travelers at Points of Entry: Looking for Evidence on Public Health Impact Mouchtouri VA, Christoforidou EP, An der Heiden M, et al. · International journal of environmental research and public health · 2019 · Systematic review DOIPubMed 31766548Full text
  11. Frequency, severity and causes of unexpected allergic reactions to food: a systematic literature review Versluis A, Knulst AC, Kruizinga AG, et al. · Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2015 · Systematic review DOIPubMed 24766413
  12. EAACI food allergy and anaphylaxis guidelines: managing patients with food allergy in the community Muraro A, Agache I, Clark A, et al. · Allergy · 2014 · Clinical guideline DOIPubMed 24905609
  13. Source attribution of human campylobacteriosis using a meta-analysis of case-control studies of sporadic infections Domingues AR, Pires SM, Halasa T, et al. · Epidemiology and infection · 2012 · Meta-analysis DOIPubMed 22214729
  14. Exploratory analyses of predictors and correlates of response to omalizumab therapy in patients with multiple food allergies Chinthrajah RS, Kulis M, Jones SM, et al. · The Journal of allergy and clinical immunology · 2026 · Randomised controlled trial DOIPubMed 41238005Full text
  15. PrecISE-a biomarker-stratified adaptive trial of 5 interventions in severe asthma: Final protocol and the baseline cohort Denlinger LC, Israel E, Moore WC, et al. · The Journal of allergy and clinical immunology · 2026 · Randomised controlled trial DOIPubMed 41707916Full text
  16. Early-life peanut oral immunotherapy associated with long-term ingestion and immunologic changes Dantzer JA, Virkud YV, Cox AL, et al. · The Journal of allergy and clinical immunology · 2026 · Randomised controlled trial DOIPubMed 42167657Full text
  17. Use of the bacterial lysate OM-85 for the primary prevention of wheezing lower respiratory illness in preschool children: a randomised, placebo-controlled trial Morgan WJ, Mauger DT, Bacharier LB, et al. · Lancet (London, England) · 2026 · Randomised controlled trial DOIPubMed 42705251
  18. Effects of pregnancy and lactation prebiotics supplementation on infant allergic disease: A randomized controlled trial Palmer DJ, Cuthbert AR, Sullivan TR, et al. · The Journal of allergy and clinical immunology · 2025 · Randomised controlled trial DOIPubMed 39173718
  19. A pediatric randomized, controlled trial of German cockroach subcutaneous immunotherapy Zoratti E, Wood R, Pomés A, et al. · The Journal of allergy and clinical immunology · 2024 · Randomised controlled trial DOIPubMed 38718950Full text
  20. Double-Blind, Placebo-Controlled Study of E-B-FAHF-2 in Combination With Omalizumab-Facilitated Multiallergen Oral Immunotherapy Wang J, Wood RA, Raymond S, et al. · The journal of allergy and clinical immunology. In practice · 2023 · Randomised controlled trial DOIPubMed 37087097Full text
  21. One-food versus six-food elimination diet therapy for the treatment of eosinophilic oesophagitis: a multicentre, randomised, open-label trial Kliewer KL, Gonsalves N, Dellon ES, et al. · The lancet. Gastroenterology & hepatology · 2023 · Randomised controlled trial DOIPubMed 36863390Full text
  22. Impact of an Intervention on Healthy Offerings and Allergenic Food Management in Restaurants: A Parallel Randomized Controlled Study Tarro L, Mandracchia F, Queral J, et al. · Nutrients · 2023 · Randomised controlled trial DOIPubMed 38068728Full text
  23. Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial Jackson DJ, Bacharier LB, Gergen PJ, et al. · Lancet (London, England) · 2022 · Randomised controlled trial DOIPubMed 35964610Full text
  24. Randomized, double-blind, placebo-controlled, food allergy challenge to olestra snacks Burks AW, Christie L, Althage KA, et al. · Regulatory toxicology and pharmacology : RTP · 2001 · Randomised controlled trial DOIPubMed 11603960
  25. Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper Pascal M, Chauhan J, Knol E, et al. · Allergy · 2025 · Review DOIPubMed 40503572Full text
  26. The epithelial barrier theory and its associated diseases Sun N, Ogulur I, Mitamura Y, et al. · Allergy · 2024 · Review DOIPubMed 39370939Full text
  27. Scope and applicability of social-ecological resilience to antimicrobial resistance Wernli D, Søgaard Jørgensen P, Parmley EJ, et al. · The Lancet. Planetary health · 2023 · Review DOIPubMed 37438004
  28. Safe Living Following Solid Organ Transplantation Blair BM · The Surgical clinics of North America · 2019 · Review DOIPubMed 30471739
  29. Travel Medicine Leung DT, LaRocque RC, Ryan ET · Annals of internal medicine · 2018 · Review DOIPubMed 29297035
  30. IgE in the diagnosis and treatment of allergic disease Platts-Mills TAE, Schuyler AJ, Erwin EA, et al. · The Journal of allergy and clinical immunology · 2016 · Review DOIPubMed 27264001Full text
  31. The restaurant syndromes Settipane GA · New England and regional allergy proceedings · 1987 · Review DOIPubMed 3302666
  32. Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 The Lancet. Infectious diseases · 2026 · Journal article DOIPubMed 41412141
  33. Global, Regional, and National Burden of Nontraumatic Subarachnoid Hemorrhage: The Global Burden of Disease Study 2021 Rautalin I, Volovici V, Stark BA, et al. · JAMA neurology · 2025 · Journal article DOIPubMed 40406922Full text
  34. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950-2023: a demographic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOIPubMed 41092927Full text
  35. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOIPubMed 41092926Full text
  36. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023 Lancet (London, England) · 2025 · Journal article DOIPubMed 41092928Full text
  37. Global, regional, and national burden of stroke and its risk factors, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021 The Lancet. Neurology · 2024 · Journal article DOIPubMed 39304265Full text
  38. Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study Ozonoff A, Jayavelu ND, Liu S, et al. · Nature communications · 2024 · Journal article DOIPubMed 38172101Full text
  39. Formononetin inhibits IgE by huPlasma/PBMCs and mast cells/basophil activation via JAK/STAT/PI3-Akt pathways Musa I, Wang ZZ, Yang N, et al. · Frontiers in immunology · 2024 · Journal article DOIPubMed 39221239Full text
  40. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: A systematic analysis for the Global Burden of Disease Study 2019 Shin YH, Hwang J, Kwon R, et al. · Allergy · 2023 · Journal article DOIPubMed 37431853Full text

Ova stranica je automatski prevedena sa engleskog. Citati i brojevi su nepromijenjeni. Pročitajte engleski original ako nešto zvuči čudno. Pročitajte engleski original